Biomedical Research Integrity: Addressing Conflicts of Interest and Ethical Challenges in Clinical Trials

This review examined the prevalence and implications of Conflicts of Interest (COI) in biomedical research. It involved an analysis of high-profile cases, including the Troglitazone safety controversy, Dr. Baselga's undisclosed pharmaceutical payments, National Institute of Health's (NIH) financial COIs, the COI involving COX-2 inhibitors, the 2008-2009 COI involving Harvard pediatric psychiatrists, and the UK University collaboration with "health-harming" industries. It also examined regulatory and ethical frameworks of COI management. The study's results show that COIs can threaten the quality of biomedical research and endanger patient health. In extreme cases, they might even lead to patient deaths. The evidence links this problem to the inconsistency of COI management policies, especially COI disclosure requirements. The findings of this research demonstrate the vague wording and poor enforcement of these requirements. To prevent the negative effects of COIs on research outcomes, consistent COI across relevant fields must be developed. For instance, leading academic journals must adopt the same COI disclosure approach to reduce ambiguity. Moreover, COI policies must address previously overlooked areas, such as the financial interests of authors' family members. The results of the study can be a good starting point for future research on addressing COIs through self-regulation. They illustrate the need for a customized COI management strategy rather than the one-size-fits-all approach.